Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease is a research paper published in European Journal of Nuclear Medicine and Molecular Imaging (2023). On theSindex it has a DataRank of 0.765. It has been cited 24 times, with 17 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0.282
From 11 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 17 citers.
NIH
Grant: U19AG032438
NIH
Grant: R01AG052550-01A1
NIH
Grant: U01AG042791
NIH
Grant: U01AG042791-S1
NIH
Grant: R01AG046179
NIH
Grant: R01AG53267-S1
NIH
Grant: P30NS098577
NIA NIH HHS
Grant: R01 AG068319
NIA NIH HHS
Grant: P30 AG066508
NIA NIH HHS
Grant: P30 AG072980
NIA NIH HHS
Grant: RF1 AG073424
NIA NIH HHS
Grant: R01 AG053267
NIA NIH HHS
Grant: UF1 AG032438
NCATS NIH HHS
Grant: UL1 TR001863
NIA NIH HHS
Grant: T32 AG058518
NIA NIH HHS
Grant: K01 AG080123
NIA NIH HHS
Grant: P30 AG066462
NIH HHS
Grant: S10 OD025214
NIA NIH HHS
Grant: R01 AG052550
FWCI
3.37
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals